公开(公告)号：US20140341970A1

公开(公告)日：2014-11-20

申请号：US14096582

申请日：2013-12-04

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K39/0011 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K39/35 ,  A61K45/06 ,  A61K2039/55511 ,  A61K2039/55572 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/41 ,  Y02A50/491

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Abstract translation: 基于在基本上均匀形式提供的合成的吡喃葡萄糖基脂质佐剂（GLA）中发现有用的免疫佐剂性质，公开了组合物和方法，包括用于诱导或增强免疫应答的疫苗和药物组合物。 在化学上，合成的GLA提供了从批次到批次的一致的疫苗组分，而不会损害天然产物佐剂的污染物或活性的波动。 还提供了疫苗和药物组合物，其包括GLA和抗原，Toll样受体（TLR）激动剂，辅助佐剂和载体如药物载体中的一种或多种。

公开(公告)号：US20140322268A1

公开(公告)日：2014-10-30

申请号：US14222481

申请日：2014-03-21

Applicant: Infectious Disease Research Institute

Inventor： Steven G. REED ,  Darrick CARTER

IPC: A61K39/39 ,  A61K39/04 ,  C07H15/20 ,  A61K39/21 ,  A61K39/245 ,  A61K39/275 ,  C07H15/12 ,  A61K39/235

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K31/665 ,  A61K31/7016 ,  A61K39/00 ,  A61K39/04 ,  A61K39/21 ,  A61K39/235 ,  A61K39/245 ,  A61K39/275 ,  A61K2039/525 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  C07H15/04 ,  C07H15/12 ,  C07H15/20

Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

Abstract translation: 提供具有以下结构（I）的化合物，特别是具有下列结构（I）的吡喃葡萄糖基脂质佐剂（GLA）化合物或其药学上可接受的盐，其中L1，L2，L3，L4，L5，L6，L7，L8，L9，L10， Y1，Y2，Y3，Y4，R1，R2，R3，R4，R5，R6如本文所定义。 还提供了用于诱导或增强免疫应答的药物组合物，疫苗组合物和相关方法。

公开(公告)号：US20220249646A1

公开(公告)日：2022-08-11

申请号：US17612893

申请日：2020-05-26

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Ryan KRAMER ,  Michelle ARCHER ,  Christopher FOX ,  Reinhard VEHRING ,  Mani ORDOUBADI ,  Mellissa GOMEZ ,  Nicholas CARRIGY

IPC: A61K39/04 ,  A61K39/39 ,  A61K9/00 ,  A61K31/7016 ,  A61K47/44 ,  A61P11/00

Abstract: The invention provides for thermostable spray dried formulations including vaccines and pharmaceutical compositions for inducing or enhancing an immune response and methods of use thereof. The spray dried formulations are a dry powder generally comprising an antigen and/or an adjuvant, a metabolizable oil, and one or more excipients.

公开(公告)号：US20220054416A1

公开(公告)日：2022-02-24

申请号：US17470874

申请日：2021-09-09

Applicant: Infectious Disease Research Institute

Inventor： Christopher B. FOX ,  Amit Praful KHANDHAR ,  Neal VAN HOEVEN ,  Jesse H. ERASMUS ,  Susan S. LIN

IPC: A61K9/127 ,  A61K9/107 ,  A61K31/713 ,  A61K39/39 ,  A61K47/10 ,  A61K47/26

Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

公开(公告)号：US20210253650A1

公开(公告)日：2021-08-19

申请号：US17241494

申请日：2021-04-27

Applicant: Infectious Disease Research Institute

Inventor： Rhea N. COLER

IPC: C07K14/35 ,  A61K39/04 ,  A61K39/00

Abstract: Provided herein are fusion polypeptides comprising at least two Mycobacterial antigens, wherein one Mycobacterial antigen is a strong central memory T cell activator, and wherein one Mycobacterial antigen is a strong effector memory T cell activator. Also provided herein are methods of making and using such fusion polypeptides for the prevention or treatment of a secondary Mycobacterium tuberculosis infection as well as for the prevention or treatment of a nontuberculous Mycobacterium infection in a mammal.

公开(公告)号：US20210069324A1

公开(公告)日：2021-03-11

申请号：US16855656

申请日：2020-04-22

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/35 ,  A61K45/06 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20200376116A1

公开(公告)日：2020-12-03

申请号：US16899729

申请日：2020-06-12

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K39/008 ,  A61K45/06 ,  A61K39/04 ,  A61K39/145 ,  A61K39/00 ,  C12N7/00

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US10792359B2

公开(公告)日：2020-10-06

申请号：US15875517

申请日：2018-01-19

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/395 ,  A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/35 ,  A61K45/06 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20200276299A1

公开(公告)日：2020-09-03

申请号：US16645456

申请日：2018-09-07

Applicant: Infectious Disease Research Institute

Inventor： Christopher B. FOX ,  Susan S. LIN

IPC: A61K39/21 ,  A61K47/24 ,  A61K39/04 ,  A61K39/015

Abstract: Provided herein are liposomal formulations containing saponin and optionally, a lipopolysaccharide. Also provided IC herein are pharmaceutical compositions and vaccine compositions comprising the liposomal formulations and an antigen. The pharmaceutical compositions and vaccine compositions are capable of eliciting or enhancing of an immune response, for example, for vaccine or therapeutic uses. Compositions and methods related to making the liposomal formulations and using the liposomal formulations for eliciting or enhancing an immune response are also provided.

公开(公告)号：US20190142935A1

公开(公告)日：2019-05-16

申请号：US16098615

申请日：2017-05-11

Applicant: Infectious Disease Research Institute

Inventor： Christopher B. Fox

IPC: A61K39/39 ,  A61P35/00 ,  A61K39/12 ,  A61K39/04 ,  A61P31/06 ,  A61P31/12 ,  A61P33/04

Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.